Boyle A. Uniform addition of ribavirin to sofosbuvir/velpatasvir for genotype 3 patients with cirrhosis: real world outcomes. THU-285.
Behandeling van anale HSIL verlaagt risico anuscarcinoom
aug 2022 | HIV, Maag-darm-leveroncologie, Virale infecties